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This book is an excellent compilation of chapters from a
variety of authors coming from pharmaceutical companies,
academia, and even one from the food and drug
administration (FDA) to inform readers about the current
paradigm in oncology clinical trials. The chapters dive much
deeper than the standard, parallel, randomized, controlled
trials that we may expect in phase III and instead start with
phase I development, move into phases II and III, and then
consider quality of life (QOL) and regulatory concerns. Thus,
reading chronologically, the book offers a generous overview
spanning oncology drug development; each chapter, how-
ever, could be read in isolation to understand that particular
phase of trial design or subject matter.
After a short introduction, chapters 2 and 3 focus on
dose‐finding, specifically through model‐based ap-
proaches. Practical advice and specific guidance for a
rigorous protocol of a small (ie, 15‐30 patients)
expansion cohort is provided at the end of chapter 2,
which fills a gap in the literature as expansion cohorts
are increasingly popular in phase I studies, but often
proposed without rigor. The fourth chapter presents
methods to evaluate an interaction between a (binary)
biomarker and (binary) treatment for binary and time‐
to‐event outcomes. The fifth chapter considers phase II
designs ranging from single‐arm historical control
trials to biomarker‐based designs including umbrella
and basket trials. A brief fifth chapter expands on mid‐
to‐late phase adaptive, Bayesian trial design, discussing
the BATTLE and I‐SPY trials as examples. The seventh
chapter discusses adaptive design in late‐stage trials
including seamless designs and sample size re‐estima-
tion. Safety monitoring and analyses across all phases
of study are the topics in chapter 8 where Frequentists
and Bayesian stopping boundaries and multistage
designs are discussed. Recommendations for safety
reporting, transparent details on subgroup analyses,
and meta‐analytic methods for combining information
from multiple trials are also presented.
Where most books would have ended, this book
continues with two important chapters. The ninth
chapter addresses including QOL as an endpoint in
oncology trials and how to address numerous statistical
challenges from these data including the role of QOL
data, multiplicity issues, and missingness of the data. The
last chapter presents regulatory pathways for drug
approval, with necessary information for anyone involved
in trial design and analysis, but one that is often ignored
by those not working directly with regulators.
While the writing is generally clear, the chapters are
greatly enhanced by including case studies or specific
examples of trials that have been implemented to
illustrate the design and/or methods discussed in the
chapters. Additionally, R code is available at the end of
two chapters (chapter 2 for a single‐agent model for
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dose escalation and a meta‐analytic model and in
chapter 4 for evaluating biomarkers and the relative
excess risk due to interaction) for direct translation of
the methods.
Overall, this book is an admirable compilation of
statistical design and methods addressing all phases of
oncological drug development. While much focus is on
model‐based, Bayesian analyses, the book still presents
more classical and Frequentist designs and methods with
ample references, thus allowing readers from many
backgrounds and preferred styles to learn more about
trial design and statistical methods in oncology.
Kelley M. Kidwell
Department of Biostatistics, School of Public Health,









Measurement error is an important and challenging topic
affecting all areas in biostatistics, including survival
analysis, longitudinal data analysis, and causal inference,
among others. Even though there are many journal
articles, which focus on measurement error, fewer
textbooks are available that contain summaries or
comprehensive discussions of the impact and approaches
to address measurement error. Existing textbooks (eg,
Fuller, 1987; Gustafson, 2004; Carroll et al., 2006;
Buonaccorsi, 2010) generally aim to introduce general
methods to deal with measurement error but pay less
attention on the discussion of measurement error in
specific datasets or particular statistical models.
Yi’s book Statistical Analysis with Measurement Error
or Misclassification: Strategy, Method and Application fills
important gaps in the available literature. First, this book
not only reviews several methods to deal with measure-
ment error, but also comprehensively discusses strategies
of correcting measurement error effect in different types
of data and model structures. Second, this book contains
supplementary problems in each chapter, which motivate
readers to brainstorm approaches to address potential
research problems. In addition to the presentation of
methodologies, this book also illustrates applications
through data analysis in each chapter, as reviewed below.
Chapter 1 mainly reviews concepts and introduces
several fundamental methods and frameworks in statis-
tical inference, including modeling, discussions of para-
meter identifiability, and estimation methods (including
likelihood method, estimating equations, generalized
method of moments, and profiling method). Moreover,
the idea of model misspecification, which is also a
concern in statistical analysis, is also briefly discussed.
In chapter 2, Yi introduces the definitions and
concepts in the measurement error literature. First, Yi
emphasizes that measurement error is a term used for
continuous variables, while misclassification is for binary
variable. In addition, Yi describes the scope of analysis of
measurement error, including modeling strategies (struc-
tural method and functional method), measurement
error mechanism (nondifferential and differential), mea-
surement error models (classical error model, Berkson
additive model, and multiplicative model), and data
requirements (validation subsample, repeated measure-
ments, instrumental data, and sensitivity analyses).
Finally, Yi presents an overview of general strategies to
handle measurement error. These methods include
likelihood‐based correction method, unbiased estimating
functions method, and method of correcting naive
estimators (eg, simulation extrapolation and regression
calibration).
The impact of measurement error in covariates for
different types of outcome data and model structures is
discussed in chapters 3 to 7. Throughout these chapters, Yi
first introduces notation, models, and the assumed model-
ing framework, and then provides strategies to correct the
effect of measurement error. Chapters 3 and 4 discuss
survival data analysis with measurement error, focusing on
the Cox proportional hazards model and the additive
hazards model, including recurrent event data. Chapter 3
first discusses feasible methods in this context for
continuous covariates, including regression calibration,
SIMEX methods, and insertion correction of the likelihood
function, followed by methods to correct bias due to
misclassification and methods for multivariate survival data
with covariate measurement error. One of methods for
recurrent event data, in chapter 4, is called the naive
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